Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Does the mono virus cause MS? The studies, one by one

Last reviewed November 15, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Epstein-Barr virus (EBV) is the virus that causes mono. About 95 in 100 people catch it at some point, usually without knowing. Multiple sclerosis (MS) is a disease where the immune system damages the coating around nerves in the brain and spinal cord.

Scientists suspected a link for decades. Below we read each key study in order and explain what it did, what it found, what it means, and what it can't tell us. Each study builds on the one before it.

Related pages: Epstein-Barr virus (EBV) infection · Multiple sclerosis (MS) · Mononucleosis (mono)

The bottom line

What we know
  • People who had mono are about twice as likely to get MS.
  • Almost everyone with MS has had EBV. In the largest study, MS almost never appeared without EBV infection first.
  • EBV is not enough on its own. Most people with EBV never get MS.
What is still open
  • Exactly how EBV leads to MS. Mistaken-identity antibodies are one strong idea, but probably not the only one.
  • Whether treating EBV can slow MS. The first big trial of an EBV-targeted treatment did not work.
  • Whether an EBV vaccine could prevent MS. A safety trial in people with early MS is running now.

The studies, in order

  1. 1. The first big review (Handel and others, 2010)
  2. 2. 10 million soldiers (Bjornevik and others, 2022)
  3. 3. Mistaken identity (Lanz and others, 2022)
  4. 4. A treatment trial (Atara Biotherapeutics, EMBOLD trial (ATA188))
  5. 5. A vaccine trial now (Moderna, HORIZON trial (mRNA-1195))
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Study 1 of 5

People who had mono get MS about twice as often

Handel and others, 2010PLoS ONE (a review of many studies)Review of many studies

What they did

The team combined 18 earlier studies, covering 19,390 people with MS and 16,007 people without it, and asked whether people who had mono were more likely to get MS.

What they found

  • People who had mono had about 2.2 times the risk of MS (relative risk 2.17; 95% range 1.97 to 2.39).
  • The result was similar across studies done in different ways and places.

What it means

A link was clear, but this kind of study can't prove EBV causes MS. Something else could make people both more likely to get mono and more likely to get MS.

What it can't tell us

  • Mono is only the visible form of EBV. Many people catch EBV with no symptoms, so this review couldn't count them.
  • Most of the studies asked people to remember past illness, which can be wrong.

Read it yourself

Next: 10 million soldiers

Study 2 of 5

MS almost never happens without EBV first

Bjornevik and others, 2022ScienceLarge observational study

What they did

The team used stored blood samples from more than 10 million US military members, taken over about 20 years. They found 955 people who later got MS and checked EBV in 801 of them, compared with 1,566 people who didn't get MS. Because the blood was stored, they could see infection before MS started.

What they found

  • Only 1 of the 801 people with MS had never had EBV.
  • Of 35 people with MS who didn't have EBV at their first sample, all but one caught EBV before MS started.
  • Catching EBV raised the risk of MS about 32-fold (hazard ratio 32.4).
  • Another common virus, cytomegalovirus (CMV), was not linked to MS.
  • A blood marker of nerve damage (serum neurofilament light, sNfL) rose only after EBV infection, not before.
  • A scan for antibodies against hundreds of viruses found no other virus that explained it.

What it means

This is the strongest evidence that EBV comes first and is likely a cause of most MS. Because the infection happened before any sign of nerve damage, MS causing EBV is very unlikely.

What it can't tell us

  • The group was young adults in the military, mostly from the US, so it may not apply to everyone.
  • It still shows a link over time, not a controlled experiment.
  • It can't explain why most people with EBV never get MS.

Read it yourself

Next: Mistaken identity

Study 3 of 5

Antibodies against EBV also attack a brain protein

Lanz and others, 2022NatureLab or animal study

What they did

The team took immune cells (B cells) from the spinal fluid of people with MS and studied the antibodies they made. They then tested the idea in mice.

What they found

  • Some antibodies stuck to both an EBV protein (EBNA1) and a protein in the brain and spinal cord (GlialCAM). The two proteins share a similar-looking piece.
  • Mice given the EBV protein got worse in a lab model of MS.
  • Antibodies that react to both proteins were more common in people with MS than in people without it.

What it means

This shows one way EBV could lead to MS. The immune system learns to fight EBV, then mistakes a brain protein for the virus. Scientists call this molecular mimicry.

What it can't tell us

  • Much of the work was in cells and mice, which may not match people.
  • Not everyone with MS has these antibodies, so it is probably one of several ways EBV causes harm.

Read it yourself

Next: A treatment trial

Study 4 of 5

The first big EBV-targeted treatment did not help

Atara Biotherapeutics, EMBOLD trial (ATA188)Randomized trial, results announced November 2023Randomized trial

What they did

ATA188 is a therapy made of donor immune cells (T cells) trained to kill cells infected with EBV. The trial randomly gave 103 people with progressive MS without recent attacks either ATA188 or a placebo.

What they found

  • It did not meet its main goal: more people improving in disability at 12 months.
  • Blood and scan tests did not show it was working either.
  • 16% of people on placebo improved, much more than the 4% to 6% the researchers expected, which made any benefit harder to see.

What it means

Even if EBV starts MS, killing EBV-infected cells years later may not reverse damage in progressive MS. It doesn't rule out EBV treatments earlier in the disease.

What it can't tell us

  • The trial was small and only included progressive MS without recent attacks.
  • Results were shared by the company. A full peer-reviewed paper was not found when we reviewed this page.

Read it yourself

Next: A vaccine trial now

Study 5 of 5

Testing an EBV vaccine in people with early MS

Moderna, HORIZON trial (mRNA-1195)Phase 2 trial, started April 2025, still recruitingSmall or early study

What they did

mRNA-1195 is an mRNA vaccine meant to train the immune system against EBV. The trial plans to enroll about 180 adults aged 18 to 55 with early MS. People get 3 shots, at the start, 2 months, and 6 months, and are followed for about 2.5 years. UK sites are led by the University of Edinburgh.

What they found

  • No results yet.
  • The main goal is safety. It will also look at MS activity on MRI and in the immune system.

What it means

If EBV drives MS, controlling it early might help. This trial is the first careful step to find out in people.

What it can't tell us

  • A safety trial can't show whether the vaccine works.
  • It tests treating people who already have MS, not preventing MS in people who don't.

Read it yourself

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.